Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Ajanta Pharma Limited ( (IN:AJANTPHARM) ) is now available.
Ajanta Pharma Limited reported a robust financial performance for the first quarter of FY 2026, with a 14% increase in revenue from operations, reaching Rs. 1,303 crore. The company’s EBITDA grew by 6% to Rs. 351 crore, while profit after tax increased by 4% to Rs. 255 crore. Excluding forex losses, EBITDA and PAT showed even stronger growth at 14% and 12%, respectively. The company also demonstrated strong cash flow metrics, with an 80% EBITDA to CFO conversion and an 82% FCF to PAT conversion. Segment-wise, the US Generic market showed the highest growth at 36%, while the Africa Institution segment saw a decline. Overall, Ajanta Pharma’s financial results reflect its strong market positioning and operational efficiency.
More about Ajanta Pharma Limited
Ajanta Pharma Limited is a specialty pharmaceutical formulation company based in Mumbai, India. The company focuses on developing, manufacturing, and marketing pharmaceutical products, with a significant presence in branded generics across India, Asia, Africa, and the US.
Average Trading Volume: 3,524
Technical Sentiment Signal: Strong Buy
Current Market Cap: 347.4B INR
Find detailed analytics on AJANTPHARM stock on TipRanks’ Stock Analysis page.